Drugs

FDA Form 483 Response Guidance Outlined

David McFarland

— 1 min read
Share

Three McDermott Will & Schulte attorneys say drug and product manufacturers may want to review their post-FDA inspection procedures and internal escalation frameworks in light of an agency 3/2026 draft guidance on responding to a form FDA-483, including timelines for response preparation, investigation planning, and executive management review. Writing in an online post, the attorneys say establishments may also consider whether their current approaches to root cause analysis, corrective and preventive action development, and effectiveness evaluation align with FDA’s expectations.

In the guidance, the post says, FDA emphasized that the FDA-483 reflects inspection observations rather than final compliance determinations, but noted that a manufacturer’s response may serve as a key input into the agency’s assessment of whether further regulatory action is warranted.

“The draft guidance reiterates FDA’s recommendation that establishments submit a single comprehensive written response within 15 business days of the form 483 issuance,” the attorneys write. “FDA explains that responses received within this timeframe are generally reviewed in detail before the agency determines whether to pursue subsequent regulatory action, whereas responses submitted after 15 business days may not delay enforcement action. FDA further recommends that form 483 responses be accurate, clear, concise, and well-organized, and demonstrate that the establishment is addressing, or actively working to address, both the specific observations and the underlying issues that led to them.”

The guidance identifies core elements that should be included in a written response, such as:

  • identification of the inspected establishment;
  • a copy of the form 483;
  • identification of the response preparer and signatory; and
  • an executive summary describing remediation activities and associated corrective actions.

The attorneys say the draft guidance places significant emphasis on robust, scientifically justified investigations. “FDA recommends that establishments develop written investigation plans that clearly define scope, methodology, and a risk-based rationale, including justification for any operations, products, or facilities excluded from the investigation,” they say. “FDA further advises that investigations extend beyond the specific observation cited to assess whether identified deficiencies may affect other drugs or batches, manufacturing processes or systems, additional facilities, or contract manufacturing or testing organizations.”

Read more